公开(公告)号：US20250017107A1

公开(公告)日：2025-01-09

申请号：US18883954

申请日：2024-09-12

Applicant: FUJIFILM Corporation

Inventor： Kouitsu SASAKI ,  Masaki MORITA ,  Saika IZUMI ,  Yasunori YONEKUTA ,  Ryoji GOTO

IPC: H10K85/60 ,  C07C225/22 ,  C07D209/96 ,  C07D263/57 ,  C07D409/06 ,  C07D487/04 ,  C07D513/04 ,  H10K30/30 ,  H10K85/20

Abstract: A first object of the present invention is to provide a photoelectric conversion element having excellent manufacturing suitability. A second object of the present invention is to provide an imaging element, an optical sensor, and a compound.
The photoelectric conversion element includes a conductive film, a photoelectric conversion film, and a transparent conductive film in this order, in which the photoelectric conversion film contains one of more of compounds represented by any of Formula (1) to (6).

公开(公告)号：US12098135B2

公开(公告)日：2024-09-24

申请号：US18075646

申请日：2022-12-06

Applicant: CASE WESTERN RESERVE UNIVERSITY

Inventor： Jonathan S. Stamler ,  William Greenlee ,  Focco van den Akker

IPC: C07D263/52 ,  C07D209/96 ,  C07D235/02

CPC classification number: C07D263/52 ,  C07D209/96 ,  C07D235/02

Abstract: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.

公开(公告)号：US20220315532A1

公开(公告)日：2022-10-06

申请号：US17596714

申请日：2020-06-22

Applicant: Gan & Lee Pharmaceuticals Co., Ltd.

Inventor： Yining ZHANG ,  Lei YIN ,  Zhenglin YAO

IPC: C07D209/96 ,  C07D401/04 ,  C07F5/02 ,  C07D403/04 ,  C07D401/14

Abstract: The present invention relates to methods for preparing 5-fluoro-4-(7′-fluoro-2′-methylspiro[cyclopentane-1,3′-indol]-5′-yl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine and a salt and an intermediate thereof The methods provided herein have improved the existing synthesis methods, simplified the preparation process and increased the yield and purity, and can well meet the requirement of large-scale industrial manufacture.

公开(公告)号：US20220281831A1

公开(公告)日：2022-09-08

申请号：US17597628

申请日：2020-07-15

Applicant: Kymera Therapeutics, Inc.

Inventor： Nan JI ,  Michael d. SINTCHAK ,  Li ZHANG ,  Xiaozhang ZHENG

IPC: C07D265/26 ,  C07D401/06 ,  C07D217/24 ,  C07D413/06 ,  C07D471/04 ,  C07D498/04 ,  C07D239/96 ,  C07D471/10 ,  C07D209/96 ,  C07D223/16 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same. The present invention also relates to compounds and methods useful for binding and modulating the activity of cereblon (CRBN), especially for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

公开(公告)号：US20220213034A1

公开(公告)日：2022-07-07

申请号：US17306390

申请日：2021-05-03

Applicant: Heptares Therapeutics Limited

Inventor： Giles Albert Brown ,  Miles Stuart Congreve ,  Mark Pickworth ,  Benjamin Gerald Tehan

IPC: C07D207/14 ,  C07D401/08 ,  C07D403/04 ,  C07D471/10 ,  C07D243/08 ,  C07D409/08 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D413/12 ,  C07D271/06 ,  C07D413/04 ,  C07D487/10 ,  C07D209/96 ,  C07D295/205 ,  C07D213/57

Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.

公开(公告)号：US11245079B2

公开(公告)日：2022-02-08

申请号：US16390675

申请日：2019-04-22

Applicant: Merck Patent GmbH

Inventor： Anja Jatsch ,  Tobias Grossmann ,  Amir Hossain Parham ,  Thomas Eberle ,  Christof Pflumm ,  Jonas Kroeber ,  Philipp Stoessel ,  Elvira Montenegro ,  Rouven Linge

IPC: H01L51/00 ,  C09K11/06 ,  C07D405/04 ,  C07D417/10 ,  C07D209/96 ,  C07D401/04 ,  C07D405/10 ,  C07D409/04 ,  C07D413/04 ,  C07D413/10 ,  C07D487/10 ,  C07D491/20 ,  C07D491/22 ,  C09B11/00 ,  C09B21/00 ,  C09B57/00 ,  H05B33/20 ,  C07D209/94 ,  C07D491/107 ,  H01L51/50

Abstract: The invention relates to compounds which are suitable for use in electronic devices, and electronic devices, in particular organic electroluminescent devices, containing said compounds.

公开(公告)号：US11014880B2

公开(公告)日：2021-05-25

申请号：US16890581

申请日：2020-06-02

Applicant: Heptares Therapeutics Limited

Inventor： Giles Albert Brown ,  Miles Stuart Congreve ,  Mark Pickworth ,  Benjamin Gerald Tehan

IPC: A61K31/015 ,  C07C211/35 ,  C07D207/14 ,  C07D401/08 ,  C07D403/04 ,  C07D471/10 ,  C07D243/08 ,  C07D409/08 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D413/12 ,  C07D271/06 ,  C07D413/04 ,  C07D487/10 ,  C07D209/96 ,  C07D295/205 ,  C07D213/57

Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.

公开(公告)号：US20210122757A1

公开(公告)日：2021-04-29

申请号：US17042646

申请日：2019-03-29

Applicant: PHENEX DISCOVERY VERWALTUNGS-GMBH

Inventor： Olaf KINZEL ,  Christoph STEENECK ,  Simon ANDERHUB ,  Martin HORNBERGER ,  Sheena PINTO ,  Barbara HERKERT ,  Thomas HOFFMANN

IPC: C07D491/048 ,  C07D307/94 ,  C07D209/96 ,  C07D405/06

Abstract: The present invention relates to novel spirocyclic compounds which act as modulators of indoleaine 2,3-dioxygenase (IDO1) and to the use of said compounds in the prophylaxis and/or treatment of diseases or conditions mediated by indoleamine 2,3-dioxygenase. The invention further relates to pharmaceutical compositions comprising the novel compounds.

公开(公告)号：US10759751B2

公开(公告)日：2020-09-01

申请号：US16295364

申请日：2019-03-07

Applicant: Heptares Therapeutics Limited

Inventor： Giles Albert Brown ,  Miles Stuart Congreve ,  Mark Pickworth ,  Benjamin Gerald Tehan

IPC: A61K31/395 ,  C07D209/96 ,  C07D207/14 ,  C07D401/08 ,  C07D403/04 ,  C07D471/10 ,  C07D243/08 ,  C07D409/08 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D413/12 ,  C07D271/06 ,  C07D413/04 ,  C07D487/10 ,  C07D295/205 ,  C07D213/57

Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.

公开(公告)号：US09871207B2

公开(公告)日：2018-01-16

申请号：US14766183

申请日：2014-02-05

Applicant: DUK SAN NEOLUX CO., LTD.

Inventor： Wonsam Kim ,  Sunhee Lee ,  Hyeryeong Kim ,  Jaewan Jang ,  Yuri Kim ,  Junghwan Park ,  Seongje Park

IPC: H01L51/00 ,  C07D495/04 ,  C07D409/14 ,  C07D209/56 ,  C07D209/96 ,  C07D487/04 ,  C07D493/04 ,  C09K11/06 ,  C07D403/04 ,  C07D403/14 ,  C07D491/048 ,  C07D307/93 ,  C07D333/78 ,  C07D209/94 ,  C07C13/62 ,  C07C13/72 ,  H01L51/50

CPC classification number: H01L51/0071 ,  C07C13/62 ,  C07C13/72 ,  C07C2603/54 ,  C07C2603/94 ,  C07D209/56 ,  C07D209/94 ,  C07D209/96 ,  C07D307/93 ,  C07D333/78 ,  C07D403/04 ,  C07D403/14 ,  C07D409/14 ,  C07D487/04 ,  C07D491/048 ,  C07D493/04 ,  C07D495/04 ,  C09K11/06 ,  C09K2211/1007 ,  C09K2211/1033 ,  C09K2211/1037 ,  C09K2211/1044 ,  C09K2211/1092 ,  H01L51/0072 ,  H01L51/0074 ,  H01L51/5016 ,  Y02E10/549

Abstract: The present invention provides a novel compound capable of improving light emitting efficiency, stability, and lifespan of the element, an organic element using the same, and an electric device for the same.